ER 127528Alternative Names: ER127528
Latest Information Update: 17 Nov 2006
At a glance
- Originator Eisai Co Ltd
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 23 Apr 2001 Preclinical development for Alzheimer's disease in Japan (Unknown route)